Influenza Vaccine Feasibility Study in Children With Persistent Asthma

• ClinicalTrials.gov Identifier: NCT02967393
• Recruitment Status: Completed
• First Posted: November 18, 2016
• Results First Posted: April 23, 2018
• Last Update Posted: April 23, 2018
• Sponsor: Vanderbilt University Medical Center
• Collaborators: Centers for Disease Control and Prevention; Duke University; Children's Hospital Medical Center, Cincinnati
• Information provided by (Responsible Party): Kathryn Edwards, Vanderbilt University Medical Center

Tracking Information

• First Submitted Date: October 31, 2016
• First Posted Date: November 18, 2016
• Results First Submitted Date: January 9, 2018
• Results First Posted Date: April 23, 2018
• Last Update Posted Date: April 23, 2018
• Actual Study Start Date: October 10, 2016
• Actual Primary Completion Date: February 1, 2017 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 22, 2018)

• Feasibility Benchmark: Number of Parents That Complete the Memory Aid 1. [ Time Frame: 15 days ]
  Memory aid 1 is a diary completed by the subjects Parent. Daily symptoms, peak flow and requires the parent to record daily symptoms, peak flow, days, post-vaccination asthma clinical symptoms and symptom scores, adverse event, fever and concomitant medication administration data for 14 days (until day 15) after vaccination.
• Feasibility Benchmark: Number of Parent Completing Collection of Adverse Event Data [ Time Frame: Day 16 to 43 ]
  Parent will collect the following data: need for new prescription or nonprescription medications for the control of asthma, an unscheduled healthcare provider visit or consultation within 42 days after vaccination, any other clinically significant event occurring at any point during the study period. Serious Adverse Events (SAEs) will also be monitored through 42 days after vaccination and will include events that result in death, were life threatening, result in subject hospitalization or prolongation of existing hospitalization, result in persistent or significant disability or incapacity. Additionally, important medical events that may not have resulted in death, were not life threatening, or did not require hospitalization might be considered SAEs when, according to appropriate medical judgment, they jeopardize the patient or subject and require medical or surgical intervention to prevent one of the outcomes listed above.
• Feasibility Benchmark: Number of Parents That Perform and Document All Home Digital Peak Flow Measurements [ Time Frame: 15 days ]
  Number of parents that perform and document all home digital peak flow measurements at least 11 days out of the 15-day monitoring period.
• Feasibility Benchmark: Number of Parents That Perform and Document the Digital Peak Flow for Day 42 [ Time Frame: Day 42 ]
  Parent will perform and document the digital peak flow for Day 42
• Feasibility Benchmark: Number of Parents That Document Nighttime Awakenings [ Time Frame: 15 days ]
  Number of parents that document nighttime awakenings for at least 11 of the 15-day monitoring period.
• Feasibility Benchmark: Number of Parents That Respond to Day 4 Call and Provide Requested Data [ Time Frame: Day 3 to 6 ]
  Number of parents that respond to Day 4 ( -1 day or + 2 days) call and provide requested data
• Feasibility Benchmark: Number of Parents That Respond to Day 8 Call and Provide Requested Data. [ Time Frame: Day 8-10 ]
  Number of parents that respond to Day 8 (plus 2 days) call and provide requested data.
• Feasibility Benchmark: Number of Parents That Respond to Day 15 Call and Provide Requested Data [ Time Frame: Day 14 to 17 ]
  Number of parents that respond to Day 15 (minus 1 or plus 2 days) call and provide requested data
• Feasibility Benchmark: Number of Parents That Respond to Day 29 Call and Provide Requested Data. [ Time Frame: Day 29-31 ]
  Number of Parents that respond to Day 29 ( Plus 2 Days) call and provide requested data.
• Feasibility Benchmark: Number of Parents That Respond to Day 44 Call [ Time Frame: Day 44-47 ]
  Number of parents that respond to Day 44 ( Plus 3 Days) call and provide requested data.
• Feasibility Benchmark: Number of Parents Completing a Satisfaction Survey [ Time Frame: 42 days ]
  Parent of each participant will be asked to complete a at the end of the study

Original Primary Outcome Measures (submitted: November 15, 2016)

To assess the feasibility of conducting a randomized prospective safety study of LAIV4 versus IIV4 during the 42 days after vaccination in children aged 5-11 years with persistent asthma of varied severity (ccIIV4 will be used as a surrogate for LAIV4) [ Time Frame: up to six months ]

The feasibility to conduct a larger safety study will be measured using "feasibility benchmarks" as outlined in the study protocol. Such benchmarks will be a percentage of eligible subjects enrolled, a percentage of subjects that complete a memory aid, and a percentage of subjects that complete all follow-up visits and phone calls.

Current Secondary Outcome Measures (submitted: March 22, 2018)

• Severe Local Reactogenicity Events During the 14 Days Post-vaccination [ Time Frame: 14 days ]
  Number of severe local reactogenicity events for 14 days after vaccination between recipients of ccIIV4 and IIV4.
• Severe Systemic Reactogenicity Events During the 14 Days Post-vaccination [ Time Frame: 14 days ]
  Number of solicited severe (not serious) systemic reactogenicity events for 14 days after vaccination between recipients of ccIIV4 and IIV4.
• Unsolicited and Severe Adverse Events [ Time Frame: 42 days ]
  The nature and frequency of the unsolicited and Severe adverse events will be described in children receiving ccIIV4 and IIV4 during the 42 days after vaccination.
• Number of Asthma Exacerbations Requiring Steroids [ Time Frame: 42 days ]
  For the purpose of this study, asthma exacerbation will be defined as: any acute episode of progressively worsening shortness of breath/dyspnea, cough, wheezing, chest tightness, and/or respiratory distress during the 42 days post-vaccination (until day 43) for which the patient receives a new prescription for systemic corticosteroids..
• Number Participants With Asthma Exacerbations Requiring Medical Attention [ Time Frame: 42 days ]
  For the purpose of this study, asthma exacerbation will be defined as: any acute episode of progressively worsening shortness of breath/dyspnea, cough, wheezing, chest tightness, and/or respiratory distress during the 42 days post-vaccination (until day 43) for which the patient seeks unscheduled medical attention (e.g., healthcare provider office or Emergency Department visit or hospitalization)

Original Secondary Outcome Measures (submitted: November 15, 2016)

• Local and Systemic reactogenicity events during the 14 days post-vaccination [ Time Frame: 14 days ]
  Proportion of subjects with solicited local and systemic reactogenicity events for 14 days after vaccination between recipients of ccIIV4 and IIV4.
• Unsolicited and Serious Adverse Events [ Time Frame: 42 days ]
  The nature and frequency of the unsolicited and serious adverse events will be described in children receiving ccIIV4 and IIV4 during the 42 days after vaccination.
• Proportions of asthma exacerbations [ Time Frame: 14 days ]
  For the purpose of this study, asthma exacerbation will be defined as: any acute episode of progressively worsening shortness of breath/dyspnea, cough, wheezing, chest tightness, and/or respiratory distress during the 14 days post-vaccination (until day 15) for which the patient seeks unscheduled medical attention (e.g., healthcare provider office or Emergency Department visit or hospitalization) or receives a new prescription for systemic corticosteroids.
• Proportions of asthma exacerbations [ Time Frame: 42 days ]
  For the purpose of this study, asthma exacerbation will be defined as: any acute episode of progressively worsening shortness of breath/dyspnea, cough, wheezing, chest tightness, and/or respiratory distress during the 42 days post-vaccination (until day 43) for which the patient seeks unscheduled medical attention (e.g., healthcare provider office or Emergency Department visit or hospitalization) or receives a new prescription for systemic corticosteroids..

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Influenza Vaccine Feasibility Study in Children With Persistent Asthma
• Official Title: Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
• Brief Summary: This study is designed to note whether a larger safety study using quadrivalent live attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated influenza vaccine (IIV4)(FLUARIX®), would be feasible in children with persistent asthma. Half of the patients in this study will receive the FLUARIX® influenza vaccine, while the other half will receive a cell cultured quadrivalent inactivated influenza vaccine (ccIIV4)(Flucelvax®) being used as a surrogate for LAIV4.

Detailed Description

The association of an increased risk in wheezing following receipt of a live-attenuated influenza vaccine in children at least 2 years of age with a prior history of asthma or wheeze remains unclear.

The Centers for Disease Control (CDC) and Prevention's Clinical Immunization Safety Assessment (CISA) planned to address a data safety gap regarding use of LAIV4 vaccine in children with asthma by conducting a 3-site randomized, non-inferiority prospective study. The main goal was to compare the safety of LAIV4 versus IIV4 in children 5-11 years with persistent asthma during the 2016-2017 influenza season. CDC and the CISA study sites developed a protocol and associated materials, and were poised to begin enrollment early during the 2016-2017 influenza season. However, after the June 22, 2016 Advisory Committee on Immunization Practices (ACIP) vote recommending against use of LAIV4 during the 2016-2017 influenza season, CDC and study investigators decided to defer implementing a study using LAIV4 during the 2016-2017 influenza season. Investigators will reconsider initiating this study during the 2017-2018 influenza season if ACIP votes to reinstate LAIV4 use or new data become available; ACIP makes recommendations annually.

The planned LAIV4 study had unique features in its design that previously had not been implemented in vaccine safety studies, including: 1) enrolling a substantial proportion of children with moderate-severe asthma 2) using digital peak flow meters and 3) collecting clinical data through multiple, complementary, measures for 42 days after vaccination. To capitalize on progress made during development of the study protocol and associated documents and procedures, CISA is proposing to carry out a study at the three sites to assess the feasibility of recruiting, enrolling, retaining, and collecting clinical data on children 5-11 years with persistent asthma of varied levels of severity in an influenza vaccine safety study. Findings from this proposed feasibility study will facilitate improving the LAIV4 study in the future if it goes forward through the CISA Project or in another venue. In 2016-2017 season, FDA approved a new influenza vaccine for use in persons aged 4 years and older, Flucelvax® Quadrivalent (ccIIV4); ACIP incorporated this vaccine into its recommendations for the 2016-2017 influenza season. Therefore ccIIV4 will be used in place of LAIV4 for this feasibility study. There is no evidence that Flucelvax® increases the risk of wheezing in asthmatic children. The feasibility study also offers an opportunity to gain some additional descriptive safety data for this new vaccine in asthmatic children.

• Study Type: Interventional
• Study Phase: Phase 4
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Other
• Condition: Asthmatic

Intervention

• Drug: ccIIV4
  Other Name: Flucelvax
• Drug: IIV4
  Other Name: Fluarix

Study Arms

• Active Comparator: IIV4
  0.5 mL intramuscular injection
  Intervention: Drug: IIV4
• Active Comparator: cc IIV4
  0.5 mL intramuscular injection
  Intervention: Drug: ccIIV4

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: March 22, 2018): 40
• Original Actual Enrollment (submitted: November 15, 2016): 50
• Actual Study Completion Date: February 1, 2017
• Actual Primary Completion Date: February 1, 2017 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Children between 5-11 years of age, inclusive, at enrollment.
• Participant must have a current diagnosis of persistent asthma.
• Parent/legal guardian must provide written informed consent and subject must provide assent as appropriate for age prior to initiation of study procedures and according to local Institutional Review Board (IRB) requirement.
• Parent/legal guardian and subject must be willing and able to comply with planned study procedures and be available for all study visits.
• Children aged 5-8 years must have received at least 2 doses of seasonal trivalent or quadrivalent influenza vaccine prior to the current influenza season. Children 9-11 years must have received at least 1 dose of seasonal trivalent or quadrivalent influenza vaccine prior to the current influenza season.
• Is in good health, other than their asthma, as determined by medical history and targeted physical examination based on medical history.
• English or Spanish literate.
• Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls and collection of information.

Exclusion Criteria:

• Acute illness and/or a reported oral temperature of ≥ 100.4°F within 72 hours prior to enrollment (this may result in a temporary delay of vaccination.
• Use of antipyretic medication during the preceding 24 hours that might mask a fever (temporary deferral).
• History of a severe allergic reaction (e.g., anaphylaxis) to any component of study influenza vaccines or a known allergy to eggs.
• Receipt of any licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to vaccination or planned receipt of any licensed vaccine within 42 days after vaccination.
• Receipt of current year's licensed influenza vaccine.
• Received an investigational agent (licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication) in the 28 days prior to enrollment or planned receipt before 42 days after vaccination.
• Has immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months.
• Has taken ≥ 20mg/day of prednisone or its equivalent, for 14 days or more within the past 28 days.
• Has know active neoplasm or a history of any hematologic malignancy.
• Has had a previous exacerbation of their asthma symptoms requiring systemic steroids within the prior 28 days, or has had a life-threatening exacerbation of asthma in the past two years (e.g. hypoxic seizure, mechanical ventilation).
• History of Guillian-Barre syndrome within 6 weeks of previous influenza vaccination.
• Has any condition that, in the opinion of the investigator, would interfere with the evaluation of the responses or would place the participant at unacceptable risk of injury.
• Has any diagnosis, current or past, of schizophrenia, bipolar disease, or other major psychiatric disorder.
• Currently taking aspirin or aspirin-containing products.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 5 Years to 11 Years (Child)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02967393
• Other Study ID Numbers: IIV4/LAIV4/CDC
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Kathryn Edwards, Vanderbilt University Medical Center
• Original Responsible Party: Kathryn Edwards, Vanderbilt University, Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics
• Current Study Sponsor: Vanderbilt University Medical Center
• Original Study Sponsor: Vanderbilt University

Collaborators

• Centers for Disease Control and Prevention
• Duke University
• Children's Hospital Medical Center, Cincinnati

Investigators

• Principal Investigator: Kathryn M Edwards, MD; Vanderbilt Vaccine Research Program

• PRS Account: Vanderbilt University Medical Center
• Verification Date: March 2018